Shred Stack (Tirzepatide + AOD9604)
Also Known As: Shred stack, Tirzepatide AOD9604 stack, Tirzepatide + AOD-9604 blend, Weight loss stack, Fat burning stack, Shred stack peptide blend
Shred Stack (Tirzepatide + AOD9604) is a research-grade Peptide stack: Tirzepatide + AOD9604 targeting GLP-1/GIP receptor activation studied in Peptide Stacks research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A powerful weight management stack combining Tirzepatide with AOD9604 to accelerate fat loss and metabolic efficiency.
At A Glance
| Category | Peptide Stacks |
|---|---|
| Compound Class | Peptide stack: Tirzepatide + AOD9604 |
| Molecular Target | GLP-1/GIP receptor activation (Tirzepatide) + Lipolytic beta-3 adrenergic pathways (AOD9604) |
| Molecular Weight | combination |
| Amino Acid Sequence | Tirzepatide + AOD9604 |
| CAS Number | n/a |
| Half-Life | ~5 days (Tirzepatide) / ~3 min (AOD9604) |
| WADA Status | prohibited |
| Evidence Tier | Research Compound |
Mechanism Of Action
It pairs a fat-releasing agent (like HGH Frag) to break down lipid stores with a metabolic booster or muscle preserver (like AOD or CJC) to ensure the freed fat is oxidized while maintaining lean mass.
Studied For
- Weight loss and fat burning
- Visceral fat reduction
- Appetite suppression
- Metabolic rate enhancement
- Lipolysis stimulation
- Insulin sensitivity improvement
- Lean mass preservation during calorie deficit
Reported Research Findings
No controlled human combination data exists; individual components have clinical evidence for obesity.
Safety And Handling Notes
Stacked incretin mimetic with fat burner may compound mild gastrointestinal side effects (nausea, satiety).
For research use only. Not for human consumption. Contains AOD9604, which is prohibited at all times under WADA 2026 S2.2.3; inherits the tirzepatide thyroid C-cell boxed warning and pancreatitis considerations.
Regulatory Status
Not FDA-approved as a stack. Tirzepatide is FDA-approved separately; AOD9604 is not approved anywhere. WADA-prohibited at all times because AOD9604 is named on the 2026 Prohibited List under S2.2.3 (growth hormone fragments), a non-Specified substance.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.